Short answer
Amneal Pharmaceuticals, Inc. (AMRX) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $796M (up 9.9% year over year) with net income of $58M.
Q2 2026 key financials · XBRL
- Revenue
- $796M
- +9.9% YoY · +10.2% QoQ
- Net income
- $58M
- +157.2% YoY · −7.4% QoQ
- Operating margin
- 16.3%
- Gross margin
- 42.0%
- EPS (diluted)
- $0.18
- +157.1% YoY · −5.3% QoQ
Source: XBRL data from the Amneal Pharmaceuticals, Inc. (AMRX) Q2 2026 10-Q on SEC EDGAR. USD.
Amneal Pharmaceuticals, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Operating cash flow $48.0M used vs $91.2M provided YoY for six months ended June 30, 2026
- Cash used in investing $144.5M vs $44.3M YoY, including $75.0M product-rights payment
- Cash provided by financing $20.3M vs $80.9M used YoY, driven by $120.5M higher debt-financing inflows
- Kashiv acquisition cash consideration $375M, expected third-quarter 2026 closing, funded through cash and borrowings
- Future opioid-settlement payments $97.6M through March 2034, including $12.7M due March 1, 2027
Risk Factors
- Risk factors not provided; excerpt begins with supplemental disclosure reference
- Kashiv Biosciences acquisition agreement dated April 21, 2026, introducing transaction-integration exposure
- Restrictive covenant agreements with Chirag and Chintu Patel dated April 21, 2026, indicating management-continuity considerations
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Amneal Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.